Filed Pursuant to Rule 424(b)(3)

Registration Statement No. 333-225995

Prospectus Supplement No. 2

(to Prospectus dated September 28, 2018 and Prospectus Supplement No. 1 dated August 2, 2019)

 

BRAINSTORM CELL THERAPEUTICS INC.

2,458,201 Shares of Common Stock

 

 

 

This prospectus supplement, together with the prospectus listed above, is to be used by certain holders of the above-referenced securities or by their pledgees, donees, transferees or other successors-in-interest in connection with the offer and sale of such securities.

 

This prospectus supplement updates and should be read in conjunction with the prospectus dated September 28, 2018 (as supplemented to date), which is to be delivered with this prospectus supplement. Such documents contain information that should be considered when making your investment decision. To the extent there is a discrepancy between the information contained herein and the information in the prospectus, the information contained herein supersedes and replaces such conflicting information.

 

This prospectus supplement consists of the below supplement to the Selling Securityholders of the prospectus.

 

Our common stock is traded on the Nasdaq Capital Market, under the symbol “BCLI”. On June 25, 2020, the last reported sales price for our common stock was $11.72 per share.

 

 

 

Investing in the Company’s securities involves risks. See “Risk Factors” beginning on page 5 of the Prospectus, as supplemented or amended by the prospectus supplements filed to date, to read about factors you should consider.

 

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

 

The date of this Prospectus Supplement No. 2 is June 26, 2020

 

 

 

 

The Selling Securityholders table on page 7 of the Prospectus is supplemented by including the following additional information:

 

   

Securities Beneficially

Owned
Prior to the Offering

  Securities Offered Hereby   Securities Beneficially
Owned
After this Offering
 

Percentage of
Common Stock
Owned After
this Offering

Name   Common
Stock
  Warrants   Common
Stock
  Common
Stock
underlying
Warrants
  Common
Stock
  Warrants    
Warberg WF VII LP     58,000**     58,000**       *
OTA LLC     300,000***     300,000***       1.0%

 

* Less than 1%

 

** Consists of Warrants assigned to Warberg WF VII LP, previously held by Selling Securityholder Warberg WF V LP.

*** Consists of Warrants assigned to OTA LLC, previously held by Selling Securityholder AIGH Investment Partners LP

 

Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Brainstorm Cell Therapeu... Charts.
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Brainstorm Cell Therapeu... Charts.